Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LCTX 
Lineage Cell Therapeutics Inc (LCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: LCTX (3-star) is a STRONG-BUY. BUY since 41 days. Simulated Profits (39.84%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.17
1 Year Target Price $4.17
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.42% | Avg. Invested days 23 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 404.19M USD | Price to earnings Ratio - | 1Y Target Price 4.17 |
Price to earnings Ratio - | 1Y Target Price 4.17 | ||
Volume (30-day avg) 7 | Beta 1.78 | 52 Weeks Range 0.37 - 1.85 | Updated Date 10/13/2025 |
52 Weeks Range 0.37 - 1.85 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -178.66% |
Management Effectiveness
Return on Assets (TTM) -13.17% | Return on Equity (TTM) -71.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 352638818 | Price to Sales(TTM) 37.03 |
Enterprise Value 352638818 | Price to Sales(TTM) 37.03 | ||
Enterprise Value to Revenue 32.31 | Enterprise Value to EBITDA -8.84 | Shares Outstanding 228356290 | Shares Floating 166384960 |
Shares Outstanding 228356290 | Shares Floating 166384960 | ||
Percent Insiders 0.42 | Percent Institutions 42.76 |
Upturn AI SWOT
Lineage Cell Therapeutics Inc
Company Overview
History and Background
Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc.) was founded in 1990. It focuses on developing and commercializing novel cell therapies for unmet medical needs. They have transitioned from a diversified biotechnology company to one primarily focused on cell therapy.
Core Business Areas
- Ophthalmology: Developing cell therapies for age-related macular degeneration (AMD), including dry AMD with geographic atrophy (GA).
- Spinal Cord Injury: Developing a spinal cord injury program focusing on restoring motor function.
- Cell Manufacturing: Developing cell manufacturing for third party services for GMP manufacturing and scale up of third party cell products.
Leadership and Structure
Brian M. Culley is the CEO. The company has a board of directors and several key management positions responsible for research and development, clinical trials, and commercial strategy.
Top Products and Market Share
Key Offerings
- OpRegen: A retinal pigment epithelium (RPE) cell therapy for the treatment of dry AMD with geographic atrophy (GA). Market share is currently negligible as it's in clinical development. Competitors include Apellis Pharmaceuticals (APLS) with Syfovre.
- OPC1: An oligodendrocyte progenitor cell (OPC) therapy for acute spinal cord injury. Market share is currently negligible as it's in clinical development. No direct competitors in Phase 3.
- RCDP196: A cell therapy for vocal chord paralysis. Market share is currently negligible as it's in pre-clinical development. There are treatments for Vocal Chord Paralysis, but none that are curative.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly growing, driven by advancements in regenerative medicine and personalized healthcare. The market is competitive, with both large pharmaceutical companies and smaller biotech firms developing novel therapies.
Positioning
Lineage Cell Therapeutics is positioned as a leader in cell therapy for ophthalmology and spinal cord injury, with a focus on allogeneic cell therapies. Their competitive advantage lies in their proprietary cell lines and manufacturing processes.
Total Addressable Market (TAM)
The TAM for cell therapies in ophthalmology and spinal cord injury is estimated to be billions of dollars. Lineage is positioning itself to capture a significant share of this market with its lead product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary cell lines and manufacturing processes
- Experienced management team
- Strong intellectual property portfolio
- Clinical-stage assets with promising data
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Need for additional funding
- Regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in cell therapy technology
- Favorable regulatory environment
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Changes in regulatory policies
- Economic downturn
Competitors and Market Share
Key Competitors
- APLS
- CRIS
- EDIT
Competitive Landscape
Lineage Cell Therapeutics competes with other cell therapy companies and pharmaceutical companies developing treatments for ophthalmology and spinal cord injury. They have advantages in their proprietary cell lines, but face competition from larger companies with more resources. Market Shares are low due to drugs being developed/ not approved, but competition in market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and partnership agreements.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of their products. Analyst estimates vary widely based on these factors.
Recent Initiatives: Recent initiatives include advancing OpRegen in its clinical program for dry AMD, ongoing development of OPC1 for spinal cord injury, and strategic partnerships to support development and commercialization.
Summary
Lineage Cell Therapeutics is a cell therapy company focused on ophthalmology and spinal cord injury. Their strengths lie in their proprietary technology and clinical-stage assets. Weaknesses include high cash burn and reliance on clinical trial success. Future success depends on navigating regulatory hurdles and competing effectively in a growing market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lineage Cell Therapeutics' SEC filings (10-K, 10-Q)
- Company press releases
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on available information and may not be precise. Projections are based on analyst estimates and are subject to change. Information is based on data before September 2024 and may not represent the current state.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lineage Cell Therapeutics Inc
Exchange NYSE MKT | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1992-03-06 | CEO, President & Director Mr. Brian M. Culley M.A., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.lineagecell.com |
Full time employees 70 | Website https://www.lineagecell.com | ||
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.